We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

65 hedge funds and large institutions have $75.5M invested in Arbutus Biopharma in 2020 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 16

59% more capital invested

Capital invested by funds: $47.6M → $75.5M (+$28M)

27% more funds holding

Funds holding: 51 → 65 (+14)

8.76% less ownership

Funds ownership: 37.88% → 29.12% (-8.8%)

20% less call options, than puts

Call options by funds: $1.5M | Put options by funds: $1.87M

44% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 16

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
65
Holders Change
+14
Holders Change %
+27.45%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
30
Increased
9
Reduced
16
Closed
16
Calls
$1.5M
Puts
$1.87M
Net Calls
-$373K
Net Calls Change
-$1.58M

Top Buyers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management IV
California
+$10.1M
2
TI
Think Investments
California
+$6.08M
3
BlackRock
BlackRock
New York
+$2.53M
4
Ameriprise
Ameriprise
Minnesota
+$1.99M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.26M

Top Sellers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
-$11.7M
2
Goldman Sachs
Goldman Sachs
New York
-$4.29M
3
Citadel Advisors
Citadel Advisors
Florida
-$3.89M
4
RI
RTW Investments
New York
-$2.71M
5
Morgan Stanley
Morgan Stanley
New York
-$1.35M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
26
Cadence Capital Management
Massachusetts
$159K +$154K +50,736 New
EMG
27
ETF Managers Group
New Jersey
$144K +$75.6K +24,853 +121%
PCM
28
Prelude Capital Management
New York
$141K +$137K +45,000 New
Assenagon Asset Management
29
Assenagon Asset Management
Luxembourg
$139K +$135K +44,362 New
BIM
30
Bogle Investment Management
Massachusetts
$131K +$127K +41,700 New
Qube Research & Technologies (QRT)
31
Qube Research & Technologies (QRT)
United Kingdom
$129K -$54.3K -17,839 -30%
Mackenzie Financial
32
Mackenzie Financial
Ontario, Canada
$125K – – –
Charles Schwab
33
Charles Schwab
California
$104K +$100K +32,912 New
EGM
34
Engineers Gate Manager
New York
$93K +$90K +29,600 New
CL
35
CSS LLC
Illinois
$84K +$81.2K +26,700 New
Two Sigma Advisers
36
Two Sigma Advisers
New York
$75K -$434K -142,600 -86%
BCM
37
Bayesian Capital Management
New York
$64K +$62.7K +20,600 New
Bank of New York Mellon
38
Bank of New York Mellon
New York
$56K +$53.9K +17,737 New
Jane Street
39
Jane Street
New York
$53K -$272K -89,356 -84%
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$43K +$17.1K +5,610 +68%
ECM
41
ExodusPoint Capital Management
New York
$41K -$12.3K -4,056 -24%
BFM
42
Boothbay Fund Management
New York
$41K +$40.2K +13,218 New
SC
43
Scotia Capital
Ontario, Canada
$37K +$398 +131 +1%
SAM
44
Secure Asset Management
Michigan
$31K – – –
IWM
45
IHT Wealth Management
Illinois
$31K +$30.4K +10,000 New
Citigroup
46
Citigroup
New York
$27K +$17K +5,600 +190%
VFA
47
Valeo Financial Advisors
Indiana
$25K +$24.3K +8,000 New
UBS Group
48
UBS Group
Switzerland
$22K -$965K -317,279 -98%
SM
49
SG3 Management
Puerto Rico
$17K +$16.6K +5,464 New
Wells Fargo
50
Wells Fargo
California
$16K +$7.41K +2,436 +84%
1
2
3 4

ABUS Hedge Fund Activity: Q3 2020 in Review

65 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2020, worth a combined $75.5M — up 59% from $47.6M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new ABUS positions and 16 closed out — a net gain of 14 holders — while 9 added to existing stakes and 16 trimmed.

The largest buyer was Foresite Capital Management IV, opening a new position worth an estimated $10.1M. The largest seller was Cowen and Company, cutting an estimated $11.7M.

  • 65 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2020, up from 51 in Q2 2020.
  • Funds reported $75.5M of Arbutus Biopharma stock for Q3 2020, up 59% quarter-over-quarter.
  • 30 funds opened new Arbutus Biopharma positions in Q3 2020 and 16 closed out, a net change of +14 holders.
  • The largest Arbutus Biopharma buyer in Q3 2020 was Foresite Capital Management IV, an estimated $10.1M added.
  • The largest Arbutus Biopharma seller in Q3 2020 was Cowen and Company, an estimated $11.7M sold.

Based on aggregated 13F filings for Q3 2020.